Front. Microbiol. Frontiers in Microbiology Front. Microbiol. 1664-302X Frontiers Media S.A. 10.3389/fmicb.2026.1793977 Correction Correction: Molecular resistance mechanisms to newly approved antibiotics (2017–2025) in WHO priority pathogens Frontiers Production Office * Frontiers Media SA, Lausanne, Switzerland Correspondence: Frontiers Production Office, production.office@frontiersin.org 13 02 2026 2026 17 1793977 22 01 2026 22 01 2026 Copyright © 2026 Frontiers Production Office. 2026 Frontiers Production Office https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Molecular resistance mechanisms to newly approved antibiotics (2017--2025) in WHO priority pathogens by Sartori M, Toppo S and Lavezzo E (2026). Front. Microbiol. 16:1719798. doi: 10.3389/fmicb.2025.1719798 antimicrobial resistance (AMR) molecular diagnostics novel antibiotics resistance mechanisms WHO priority pathogens section-at-acceptance Antimicrobials, Resistance and Chemotherapy

The hierarchical structure of sections and sub-sections were incorrectly formatted in the final version of the article.

The bullet points starting at “In E. coli, expression of the AmpC…” are intended as sub-sections of “Enzymatic inactivation”, page 4, Aztreonam-avibactam.

The sections starting at “Alterations in iron transport systems.” are intended as sub-sections of “Resistance mechanisms”, page 5, Cefiderocol.

The sections starting at “A. baumannii:” are sub-subsections of the section “Alterations in iron transport systems”, page 6, Cefiderocol.

Similarly, the sections starting at “Reduced outer membrane permeability.” are sub-sections of “Resistance mechanisms”, page 7, Meropenem-vaborbactam.

The sections at “OmpK35 inactivation:” are sub-sections of the “K. pneumoniae”, page 7, Meropenem-vaborbactam.

Sections beginning at lines “Mutations in ddn” are sub-sections of “Resistance mechanisms”, page 8, Pretomanid.

Sections beginning at “Increased efflux pump expression” are sub-sections of “Resistance mechanisms”, page 8, Lefamulin.

Sections beginning at lines “Efflux pump overexpression” are sub-sections of “Resistance mechanisms”, page 9, Omadacycline.

Sections beginning at lines “Efflux pump overexpression” are sub-sections of “Resistance mechanisms”, page 9, Eravacycline.

Sections beginning at “Modification of target sites” are sub-sections of “Resistance mechanisms”, page 10, Plazomicin.

Sections beginning at “Enzymatic inactivation” are sub-sections of “Resistance mechanisms”, page 11, Rifamycin SV.

Sections beginning at “Target site modifications” are sub-sections of “General resistance mechanisms”, page 12, Quinolones and fluoroquinolones.

Sections beginning at “Increased efflux pump expression” are sub-sections of “Resistance mechanisms”, page 12, Delafloxacin.

There was a mistake in Table 2 as published. In line 2 of the table, regarding “Cefepime and enmetazobactam” antibiotic, the column “Main use” reports “HABP, cUTIs, and cIAIs”. The corrected Table 2 appears below, where “cIAIs” has been removed for that drug.

Antimicrobial drugs approved by FDA and/or EMA since 2017.

Entry Drug name Approval year Drug class (subclass) Main use
1. Aztreonam and avibactam 2024 EMA β-lactams and BLICs Monobactam and non-β-lactam β-lactamase inhibitor cUTIs, cIAIs, HABP, VABP, and Gram-negative blood stream infections with limited treatment options
2. Cefepime and enmetazobactam 2024 FDA β-lactams and BLICs Cephalosporin and β-lactamase inhibitor HABP and cUTIs
3. Ceftobiprole 2024 FDA β-lactams and BLICs Cephalosporin ABSSSI, CABP and SAB
4. Sulbactam and durlobactam 2023 FDA β-lactams and BLICs β-lactamase inhibitors A. baumannii–calcoaceticus complex HABP and VABP in adult patients aged
5. Cefiderocol 2019 FDA 2020 EMA β-lactams and BLICs Cephalosporin cUTIs, HABP, VABP, and other serious Gram-negative infections with limited treatment options
6. Imipenem, cilastatin, and relebactam 2019 FDA 2020 EMA β-lactams and BLICs Carbapenem, renal dehydropeptidase inhibitor, and β-lactamase inhibitor cUTIs, cIAIs, and HABP/VABP
7. Meropenem and vaborbactam 2017 FDA 2018 EMA β-lactams and BLICs Carbapenem and β-lactamase inhibitor cUTIs, cIAIs, HAP/VAP, and bacteremia or other infections caused by CRE with limited treatment options
8. Pretomanid 2019 FDA 2020 EMA Nitroimidazole Pulmonary TB (MDR-TB and RR-TB)
9. Lefamulin 2019 FDA 2020 EMA Pleuromutilin CABP
10. Omadacycline 2018 FDA Tetracycline ABSSSI, CABP
11. Eravacycline 2018 FDA 2018 EMA Tetracycline cIAIs
12. Plazomicin 2018 FDA Aminoglycoside cUTIs
13. Rifamycin 2018 FDA Rifamycin Travelers' diarrhea caused by non-invasive strains of Escherichia coli
14. Delafloxacin 2017 FDA 2019 EMA Fluoroquinolone ABSSSIs, CABP
15. Gepotidacin 2025 FDA Triazaacenaphthylenes uUTI

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland